Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cara Therapeutics (CARA) Reports Positive Data from HAL Trial of CR845 IV Formulation
- Arena Pharma (ARNA) Gains; Reports Results of Investigational Pilot Study of Coadministration of Lorcaserin and Phentermine
- Myos Corporation (MYOS) Reports Data Showing Fortetropin's Anti-Inflammatory Properties
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!